| Dipul V Patadia, MD | |
|
3815 Highland Ave, Downers Grove, IL 60515-1500 | |
| (630) 275-5900 | |
| Not Available |
| Full Name | Dipul V Patadia |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 19 Years |
| Location | 3815 Highland Ave, Downers Grove, Illinois |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184893687 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 036-119280 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Adventist Hinsdale Hospital | Hinsdale, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cepamerica Illinois Llp | 3274793633 | 407 |
| Illinois Emergency Medicine Specialists Llc | 6103071808 | 34 |
News Archive
Cynosure, Inc., today announced four international regulatory approvals that extend the reach of the company's proprietary aesthetic laser systems in Asia and South America.
According to the National Osteoporosis Foundation, 10 million Americans have osteoporosis, and another 18 million have low bone mass, making them at risk for osteoporosis. Often referred to as the silent disease because it develops slowly over a number of years without symptoms, osteoporosis is characterized by a gradual weakening of the bones due to bone loss, which can lead to fractures.
Lexicon Pharmaceuticals, Inc. announced that data from the Phase 2b clinical trial of LX4211 are being presented today as a Clinical Sciences Special Report in the Emerging Therapeutics for Diabetes and Dyslipidemia section of the American Heart Association (AHA) Scientific Sessions Conference held in Los Angeles, California.
Simoctocog alfa (trade name Nuwiq) has been approved since July 2014 for people with type A haemophilia, an inherited disorder that impairs blood clotting. The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether this new drug offers an added benefit over the appropriate comparator therapy. Such an added benefit cannot be derived from the dossier, however, because the drug manufacturer did not submit any suitable data.
› Verified 3 days ago
| Entity Name | Dupage Emergency Physicians Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255323481 PECOS PAC ID: 6507854288 Enrollment ID: O20040503000606 |
News Archive
Cynosure, Inc., today announced four international regulatory approvals that extend the reach of the company's proprietary aesthetic laser systems in Asia and South America.
According to the National Osteoporosis Foundation, 10 million Americans have osteoporosis, and another 18 million have low bone mass, making them at risk for osteoporosis. Often referred to as the silent disease because it develops slowly over a number of years without symptoms, osteoporosis is characterized by a gradual weakening of the bones due to bone loss, which can lead to fractures.
Lexicon Pharmaceuticals, Inc. announced that data from the Phase 2b clinical trial of LX4211 are being presented today as a Clinical Sciences Special Report in the Emerging Therapeutics for Diabetes and Dyslipidemia section of the American Heart Association (AHA) Scientific Sessions Conference held in Los Angeles, California.
Simoctocog alfa (trade name Nuwiq) has been approved since July 2014 for people with type A haemophilia, an inherited disorder that impairs blood clotting. The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether this new drug offers an added benefit over the appropriate comparator therapy. Such an added benefit cannot be derived from the dossier, however, because the drug manufacturer did not submit any suitable data.
› Verified 3 days ago
| Entity Name | Dupage Emergency Physicians Convenient Care Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922000363 PECOS PAC ID: 6608840046 Enrollment ID: O20040823000566 |
News Archive
Cynosure, Inc., today announced four international regulatory approvals that extend the reach of the company's proprietary aesthetic laser systems in Asia and South America.
According to the National Osteoporosis Foundation, 10 million Americans have osteoporosis, and another 18 million have low bone mass, making them at risk for osteoporosis. Often referred to as the silent disease because it develops slowly over a number of years without symptoms, osteoporosis is characterized by a gradual weakening of the bones due to bone loss, which can lead to fractures.
Lexicon Pharmaceuticals, Inc. announced that data from the Phase 2b clinical trial of LX4211 are being presented today as a Clinical Sciences Special Report in the Emerging Therapeutics for Diabetes and Dyslipidemia section of the American Heart Association (AHA) Scientific Sessions Conference held in Los Angeles, California.
Simoctocog alfa (trade name Nuwiq) has been approved since July 2014 for people with type A haemophilia, an inherited disorder that impairs blood clotting. The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether this new drug offers an added benefit over the appropriate comparator therapy. Such an added benefit cannot be derived from the dossier, however, because the drug manufacturer did not submit any suitable data.
› Verified 3 days ago
| Entity Name | Cepamerica Illinois Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912283110 PECOS PAC ID: 3274793633 Enrollment ID: O20120322000587 |
News Archive
Cynosure, Inc., today announced four international regulatory approvals that extend the reach of the company's proprietary aesthetic laser systems in Asia and South America.
According to the National Osteoporosis Foundation, 10 million Americans have osteoporosis, and another 18 million have low bone mass, making them at risk for osteoporosis. Often referred to as the silent disease because it develops slowly over a number of years without symptoms, osteoporosis is characterized by a gradual weakening of the bones due to bone loss, which can lead to fractures.
Lexicon Pharmaceuticals, Inc. announced that data from the Phase 2b clinical trial of LX4211 are being presented today as a Clinical Sciences Special Report in the Emerging Therapeutics for Diabetes and Dyslipidemia section of the American Heart Association (AHA) Scientific Sessions Conference held in Los Angeles, California.
Simoctocog alfa (trade name Nuwiq) has been approved since July 2014 for people with type A haemophilia, an inherited disorder that impairs blood clotting. The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether this new drug offers an added benefit over the appropriate comparator therapy. Such an added benefit cannot be derived from the dossier, however, because the drug manufacturer did not submit any suitable data.
› Verified 3 days ago
| Entity Name | Illinois Emergency Medicine Specialists Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003150962 PECOS PAC ID: 6103071808 Enrollment ID: O20130304000132 |
News Archive
Cynosure, Inc., today announced four international regulatory approvals that extend the reach of the company's proprietary aesthetic laser systems in Asia and South America.
According to the National Osteoporosis Foundation, 10 million Americans have osteoporosis, and another 18 million have low bone mass, making them at risk for osteoporosis. Often referred to as the silent disease because it develops slowly over a number of years without symptoms, osteoporosis is characterized by a gradual weakening of the bones due to bone loss, which can lead to fractures.
Lexicon Pharmaceuticals, Inc. announced that data from the Phase 2b clinical trial of LX4211 are being presented today as a Clinical Sciences Special Report in the Emerging Therapeutics for Diabetes and Dyslipidemia section of the American Heart Association (AHA) Scientific Sessions Conference held in Los Angeles, California.
Simoctocog alfa (trade name Nuwiq) has been approved since July 2014 for people with type A haemophilia, an inherited disorder that impairs blood clotting. The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether this new drug offers an added benefit over the appropriate comparator therapy. Such an added benefit cannot be derived from the dossier, however, because the drug manufacturer did not submit any suitable data.
› Verified 3 days ago
| Entity Name | Osf Multi-specialty Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922445527 PECOS PAC ID: 3678889789 Enrollment ID: O20150904000279 |
News Archive
Cynosure, Inc., today announced four international regulatory approvals that extend the reach of the company's proprietary aesthetic laser systems in Asia and South America.
According to the National Osteoporosis Foundation, 10 million Americans have osteoporosis, and another 18 million have low bone mass, making them at risk for osteoporosis. Often referred to as the silent disease because it develops slowly over a number of years without symptoms, osteoporosis is characterized by a gradual weakening of the bones due to bone loss, which can lead to fractures.
Lexicon Pharmaceuticals, Inc. announced that data from the Phase 2b clinical trial of LX4211 are being presented today as a Clinical Sciences Special Report in the Emerging Therapeutics for Diabetes and Dyslipidemia section of the American Heart Association (AHA) Scientific Sessions Conference held in Los Angeles, California.
Simoctocog alfa (trade name Nuwiq) has been approved since July 2014 for people with type A haemophilia, an inherited disorder that impairs blood clotting. The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether this new drug offers an added benefit over the appropriate comparator therapy. Such an added benefit cannot be derived from the dossier, however, because the drug manufacturer did not submit any suitable data.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dipul V Patadia, MD Po Box 88495, Dept A, Chicago, IL 60680-1495 Ph: (630) 734-0200 | Dipul V Patadia, MD 3815 Highland Ave, Downers Grove, IL 60515-1500 Ph: (630) 275-5900 |
News Archive
Cynosure, Inc., today announced four international regulatory approvals that extend the reach of the company's proprietary aesthetic laser systems in Asia and South America.
According to the National Osteoporosis Foundation, 10 million Americans have osteoporosis, and another 18 million have low bone mass, making them at risk for osteoporosis. Often referred to as the silent disease because it develops slowly over a number of years without symptoms, osteoporosis is characterized by a gradual weakening of the bones due to bone loss, which can lead to fractures.
Lexicon Pharmaceuticals, Inc. announced that data from the Phase 2b clinical trial of LX4211 are being presented today as a Clinical Sciences Special Report in the Emerging Therapeutics for Diabetes and Dyslipidemia section of the American Heart Association (AHA) Scientific Sessions Conference held in Los Angeles, California.
Simoctocog alfa (trade name Nuwiq) has been approved since July 2014 for people with type A haemophilia, an inherited disorder that impairs blood clotting. The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether this new drug offers an added benefit over the appropriate comparator therapy. Such an added benefit cannot be derived from the dossier, however, because the drug manufacturer did not submit any suitable data.
› Verified 3 days ago
Thomas J Mullin Jr., MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: Advocate Good Samaritan Hospital, 3815 Highland Ave, Downers Grove, IL 60515 Phone: 630-275-5900 Fax: 630-734-1560 | |
Dr. Michael Gucci, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2655 Warrenville Rd Ste 500, Downers Grove, IL 60515 Phone: 855-783-6877 | |
Marc R. Spiller, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3815 Highland Ave, Downers Grove, IL 60515 Phone: 877-485-4474 | |
Yogesh P Vajaria, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 3815 Highland Ave, Advocate Good Samaritan Hospital, Downers Grove, IL 60515 Phone: 630-275-5900 Fax: 630-734-1560 | |
Bradly Healton, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 30000 Woodcreek Dr, 200b, Downers Grove, IL 60515 Phone: 636-087-4299 Fax: 630-968-1622 | |
Valerie Phillips, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3815 Highland Ave, Downers Grove, IL 60515 Phone: 630-275-5900 |